Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892887 | 0.95 | SNCA (0.75) | SNCA | |
| SCHEMBL891911 | 0.93 | SNCA (0.63) | SNCA | |
| SCHEMBL892089 | 0.93 | SNCA (0.59) | SNCA | |
| SCHEMBL892832 | 0.93 | SNCA (0.62) | SNCA | |
| SCHEMBL30487854 | 0.93 | SNCA (0.59) | SNCANOTUM | |
| SCHEMBL21809413 | 0.93 | SNCA (0.59) | SNCANOTUM | |
| SCHEMBL30487855 | 0.93 | SNCA (0.59) | SNCANOTUM | |
| SCHEMBL21809408 | 0.92 | SNCA (0.62) | SNCANOTUM | |
| SCHEMBL21809407 | 0.91 | SNCA (0.57) | SNCANOTUM | |
| SCHEMBL30487846 | 0.91 | SNCA (0.57) | SNCANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12178805-B2 | Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders | REMYND N.V. (BE) | 2024-12-31 | — | — | US | claimed |
| US-11939324-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | REMYND N.V. (BE) | 2024-03-26 | — | — | US | claimed |
| EP-3621963-B1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | REMYND N V (BE) | 2024-01-24 | — | — | EP | claimed |
| CN-110650955-B | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | 瑞敏德股份有限公司 | 2023-07-25 | — | — | CN | claimed |
| US-11548881-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | REMYND N.V. (BE) | 2023-01-10 | — | — | US | claimed |
| US-20200253934-A1 | INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2020-08-13 | — | — | US | claimed |
| US-20200095238-A1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | CISTIM (BE) | 2020-03-26 | — | — | US | claimed |
| CN-110650955-A | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | 瑞敏德股份有限公司 | 2020-01-03 | — | — | CN | claimed |
| US-8618138-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2013-12-31 | — | — | US | claimed |
| US-12178805-B2 | Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders | REMYND N.V. (BE) | 2024-12-31 | — | — | US | disclosed |
| US-11939324-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | REMYND N.V. (BE) | 2024-03-26 | — | — | US | disclosed |
| EP-3621963-B1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | REMYND N V (BE) | 2024-01-24 | — | — | EP | disclosed |
| CN-110650955-B | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | 瑞敏德股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230099111-A1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-03-30 | — | — | US | disclosed |
| US-8618138-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2013-12-31 | — | — | US | disclosed |
| EP-2440550-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010142801-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | SNCA 1/4885NOTUM 1795/4885 |
| US-20200095238-A1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | MAPT, PSEN1, PSEN2 | SNCA 34/4885NOTUM 1671/4885 |
| US-12178805-B2 | Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders | PDE4A, PDE12, PDE2A | SNCA 294/4885NOTUM 2205/4885 |
| US-20230099111-A1 | COMPOUNDS FOR THE TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND OTHER CNS DISORDERS | MAPT, PSEN1, PSEN2 | SNCA 34/4885NOTUM 1671/4885 |
| US-11548881-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | MAPT, PSEN1, PSEN2 | SNCA 34/4885NOTUM 1671/4885 |
| US-20200253934-A1 | INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS | PDE4A, PDE12, PDE2A | SNCA 294/4885NOTUM 2205/4885 |
| US-11939324-B2 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders | MAPT, PSEN1, PSEN2 | SNCA 34/4885NOTUM 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.